A Phase 1 interventional study of Esomeprazole Capsule and Esomeprazole Tablet in Healthy Participants, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-14.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the bioequivalence of esomeprazole 40 milligram (mg) tablets and capsules.
The drug being tested in this study is called esomeprazole. Esomeprazole is being tested in healthy participants in order to evaluate the bioequivalence between a single oral dose of esomeprazole tablet and capsule. The study will enroll 52 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment sequences:
All participants will be asked to take one capsule or tablet on Day 1 of each Intervention Period based on the treatment sequence to which the participant has been assigned.
This single center trial will be conducted in the United States. The overall duration to participate in this study is 36 days. Participants will visit the clinic on Day -1 and remained confined until Day 1 of Intervention Period 1 and 2. A washout period of minimum 6 days will be maintained between the dose in each Intervention Period.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
Drug: Esomeprazole Capsule · Drug: Esomeprazole Tablet
Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
Drug: Esomeprazole Capsule · Drug: Esomeprazole Tablet
Esomeprazole Capsule
Also known as: Nexium
Esomeprazole Tablet
Also known as: Nexium
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose
AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose
Cmax: Maximum Observed Plasma Concentration for Esomeprazole
Time frame: Day 1 pre-dose and at multiple time points (up to 10 hours) post-dose
Participants took part in the study at 1 investigative site in the United States from 27 March 2017 to 13 May 2017.
| Milestone | Regimen A + Regimen B | Regimen B + Regimen A |
|---|---|---|
| Started | 26 | 26 |
| Completed | 26 | 26 |
| Not completed | 0 | 0 |
| Milestone | Regimen A + Regimen B | Regimen B + Regimen A |
|---|---|---|
| Started | 26 | 26 |
| Completed | 25 | 25 |
| Not completed | 1 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Regimen A + Regimen B | Regimen B + Regimen A |
|---|---|---|
| Started | 25 | 25 |
| Completed | 25 | 25 |
| Not completed | 0 | 0 |
| hour*nanogram per milliliter (h*ng/mL) | Regimen A | Regimen B |
|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole | 1908.0 ± 66.0 | 1922.2 ± 57.9 |
| h*ng/mL | Regimen A | Regimen B |
|---|---|---|
| AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time t for Esomeprazole | 1884.6 ± 64.3 | 1882.6 ± 57.5 |
| nanogram per milliliter (ng/mL) | Regimen A | Regimen B |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Esomeprazole | 933.29 ± 44.5 | 872.38 ± 43.5 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regimen A | 0/51 (0%) | 0/51 (0%) | 4/51 (7.8%) |
| Regimen B | 0/51 (0%) | 0/51 (0%) | 3/51 (5.9%) |
| Event | Regimen A | Regimen B |
|---|---|---|
| HeadacheNervous system disorders | 3/51 | 2/51 |
| DysmenorrhoeaReproductive system and breast disorders | 0/51 | 1/51 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/51 | 1/51 |
The safety analysis set included all participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| Mean | 32.4 ± 9.64 | 33.3 ± 7.83 | 32.8 ± 8.71 |
| Sex: Female, Male(Participants) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| Female | 9 | 11 | 20 |
| Male | 17 | 15 | 32 |
| Race (NIH/OMB)(Participants) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 11 | 19 |
| White | 18 | 13 | 31 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| United States | 26 | 26 | 52 |
| Weight(kilogram) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| Mean | 73.3 ± 12.83 | 75.3 ± 13.37 | 74.3 ± 13.01 |
| Height(centimeter) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| Mean | 173.4 ± 10.36 | 170.7 ± 10.95 | 172.0 ± 10.65 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| Mean | 24.3 ± 2.77 | 25.7 ± 2.89 | 25.0 ± 2.89 |
| Smoking Status(Participants) | Regimen A + Regimen B | Regimen B + Regimen A | Total |
|---|---|---|---|
| Never smoked | 18 | 24 | 42 |
| Ex-smoker | 8 | 2 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in May 2017, 1 month.
Results were first posted in Jun 2019, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole